Perrigo Company plc (PRGO) Stock Analysis

Perrigo drew 12.9% of its 2025 consolidated net sales from Walmart, its largest customer, with the top ten customers combining for 47%, while no single product line exceeds 5% of revenue across a self-care portfolio manufactured primarily in the U.S. alongside facilities in the U.K., Belgium, France, Germany, and China. The company operates through two segments, Consumer Self-Care Americas and Consumer Self-Care International, selling in North America and more than 30 countries, mostly in Europe.

Perrigo earns most of its revenue selling store-brand, private-label self-care products across categories such as cough/cold, digestive health, oral care, skin care, women's health, vitamins, and infant formula to national retail drug chains, supermarkets, mass merchandisers, and wholesalers who resell them below national-brand prices, alongside a smaller portfolio of owned brands including Opill, Mederma, and Compeed. Competitors on the store-brand side include Dr. Reddy's, LNK International, PL Developments, Aurobindo, and Sun Pharmaceuticals, while branded consumer-health rivals include Haleon, Kenvue, Procter & Gamble, and Reckitt Benckiser. The CSCA segment sells through U.S. and Canadian retail and e-commerce channels, while CSCI distributes through pharmacies, wholesalers, and para-pharmacies in more than 30 countries. Perrigo maintains several single-source supplier relationships for certain raw materials and dosage forms, chosen either because alternative sources are unavailable or because the arrangement offers regulatory, quality, or pricing advantages.